Scientific Advisors

Lacerta Therapeutics scientific advisors consist of scientists with deep scientific and clinical expertise in AAV gene therapy related to our proprietary technologies and clinical programs.


Nicholas Muzyczka, PhD
Co-founder

See Bio under Board of Directors

 

Barry Byrne, MD, PhD
Co-founder

See Bio under Board of Directors

 

Arun Srivastava, PhD
Co-founder

Dr. Srivastava is a Professor of Pediatrics and Chief of the Division of Cellular and Molecular Therapy at the University of Florida with over 30 years of experience with AAV vectors and was the first to completely sequence AAV DNA. He has made many basic contributions to AAV biology. Most recently, he has developed over 250 different AAV capsid mutants using rational design approaches that increase transduction by up to two orders of magnitude in animal models.

 

Coy Heldermon, MD, PhD
Co-founder

Dr. Heldermon is an Associate Professor of Medicine at the University of Florida. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He has extensive preclinical data for the use of AAV to treat Sanfilippo syndrome B.

 

Sergei Zolothukin, PhD
Co-founder

Dr. Zolotukhin is an Associate Professor of Pediatrics at the University of Florida with 30 years of experience in the gene therapy field. He has developed many of the methods for purification and quality control of AAV vectors and has pioneered the development of improved capsid engineering methods and baculovirus vector production platforms.

 

Kenneth Warrington, Jr., PhD
Co-founder

Dr. Warrington has a broad expertise across the AAV gene therapy product development continuum including discovery, process development/scale up for clinical grade manufacturing, CMC and product characterization using a broad range of platforms, and GMP-compliant testing to support IND-enabling preclinical and early stage clinical programs.

 

Ronald Mandel, PhD
Co-founder

Dr. Mandel is a Professor of Neurosciences at the University of Florida with over 25 years experience in the study of neurodegenerative diseases, with a particular focus on Parkinson's disease. His laboratory is a leader in preclinical studies in the use of AAV for gene therapy. Prior to accepting the academic appointment in the Powell Gene Therapy Center he developed gene therapy applications for the brain in Somatix Inc. and CellGenesys Inc.

 

Todd E. Golde, MD, PhD
Co-founder

Dr. Golde is a Professor of Neuroscience and the Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida where he directs a robust program of scientific discovery aimed at translating basic discoveries in neurodegenerative disease into diagnostics and treatments for patients with Alzheimer's and Parkinson's disease.

 

Edgardo Rodriguez, PhD
Co-founder

Dr. Rodríguez-Lebrón has expertise in AAV-based gene therapies that make use of microRNA molecules and gene editing tools to suppress the expression of these proteins in CNS resident cells. He uses model systems to test novel gene-based therapies that prevent, halt or reverse neurodegenerative processes caused by the abnormal accumulation of misfolded proteins.